GIST pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
14 of 17 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
anti-PD-L1 (with imatinib) 1
Atezolizumab + ImatinibPhase 2
No dated milestone in 2025 to 2030
anti-PD-L1 (with regorafenib) 1
Envafolimab + RegorafenibPhase 2
No dated milestone in 2025 to 2030
Class not reported 1
DCC-3009Phase 1/2
No dated milestone in 2025 to 2030
HIF-2 alpha inhibitor 1
BelzutifanPhase 2
No dated milestone in 2025 to 2030
KIT type I TKI plus type II TKI combination 1
FDA PDUFA target action date (GIST, with sunitinib), Nov 30, 2026
KIT/PDGFRA TKI (type II) 1
ImatinibApproved
No dated milestone in 2025 to 2030
KIT/PDGFRA type I TKI 1
AvapritinibApproved
No dated milestone in 2025 to 2030
multi-kinase TKI 2
RegorafenibApproved
No dated milestone in 2025 to 2030
Olverembatinib (HQP1351)Phase 3
No dated milestone in 2025 to 2030
multi-kinase TKI (type II) 1
SunitinibApproved
No dated milestone in 2025 to 2030
selective KIT TKI 2
No dated milestone in 2025 to 2030
NB003Phase 2/3
No dated milestone in 2025 to 2030
switch-control KIT/PDGFRA TKI 1
RipretinibApproved
No dated milestone in 2025 to 2030
VEGFR2 TKI (with paclitaxel) 1
Rivoceranib + PaclitaxelPhase 2
No dated milestone in 2025 to 2030